Akron Biotech appoints new Scientific Advisory Board, further expanding its cell and gene therapy industry expertise

Boca Raton, FL, US, April 7, 2021 – Akron Biotech, a leading developer and manufacturer of cGMP-compliant ancillary materials for cell and gene therapy development and commercialization, today announces the appointment of a new Scientific Advisory Board. The board is comprised of world-leading scientists and experts in the cell and gene therapy field. It will

Enhancing the safety of virus-inactivated ancillary materials through neutralizing antibodies

The discovery of antibodies in the late nineteenth century marks one of the most significant advancements in our understanding of the human immune system. It catalyzed over a century of rapidly evolving investigations and characterizations of the invisible biochemical mechanisms that keep us safe every day. This blossoming immunological understanding continues to progress alongside our

Going Green, the Akron Way

One small act can change the world, which is why we at Akron Biotech began our work with One Tree Planted in 2018. The mission behind One Tree Planted is simple: While the problems around climate change and deforestation are vast, planting a tree is something anyone can do. The non-profit is committed to planting

COVID-19 Response

Akron Biotech is committed to help defeat COVID-19 – Together we cure Coronavirus disease 2019 (COVID-19) is a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Symptoms tend to appear 2-14 days after exposure to the virus and can range from mild to severe, with some patients requiring  hospitalization1. In response to this

Building a Robust Supply Chain to Enable Cell and Gene Therapy Development

In the burgeoning cell and gene therapy market, companies at all stages of pre-clinical and clinical development are faced with a similar set of challenges of producing effective, standardized, and compliant therapies. The novelty of these technologies combined with the rigorous quality controls surrounding the materials and production process require a specialized approach for starting

The future is 20/20

What a year it has been at Akron! We’ve continued to raise the bar, focusing on what matters most – enabling the development and commercialization of tomorrow’s cures. We’ve done this by securing the supply of critical GMP materials for our customers, the institutions and companies leading the way. This has been a big year

Join us in Orlando and Amsterdam this week as we present our staged approach to cGMP ancillary materials

Ancillary materials play a critical role in the manufacture of cell and gene therapies, and best practices for their quality management are the subject of ongoing discussion. Given that these therapies cannot be sterilized, ancillary material quality is critical to clinical advancement and commercialization. At Akron, we believe that a harmonized definition of what constitutes

Stoichiometry via mass spectrometry sheds light on the T cell metabolism

The field of immunometabolism has attracted growing attention in recent years due to the high potential for the development of cancer immunotherapies. Upon activation, T lymphocytes (T cells) undergo significant metabolic changes that allow them to mediate immune responses. Stimulating these and other immune cells has important outcomes beyond energy production (Fig. 1). A key